EXAGEN INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EXAGEN INC. (XGN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $980.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $980.00K, a 121.22% increase year-over-year.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $655.00K, a 57.07% increase year-over-year.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $593.00K, a 173.27% increase year-over-year.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $443.00K, a 20.89% decline year-over-year.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.16M, a 22.40% increase from fiscal 2024.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.76M, a 51.26% decline from fiscal 2023.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.62M, a 23.11% decline from fiscal 2022.
- EXAGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.70M, a 0.51% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $980.00K 10-Q · filed 2026-08-04 | $1.64M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $655.00K 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $2.16M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $593.00K 10-Q · filed 2025-11-04 | $1.04M derived: sum of 2 quarters · filed 2026-08-04 | $1.45M derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $443.00K 10-Q · filed 2026-08-04 | $860.00K derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $417.00K 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $1.76M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $217.00K 10-Q · filed 2025-11-04 | $777.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.33M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $560.00K 10-Q · filed 2025-11-04 | $1.11M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $553.00K 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $3.62M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $890.00K 10-Q · filed 2024-11-12 | $1.87M derived: sum of 2 quarters · filed 2024-11-12 | $2.85M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $978.00K 10-Q · filed 2024-11-12 | $1.96M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $986.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $4.70M 10-K · filed 2024-03-18 | |||
| 2022-09-30 | $1.31M 10-Q · filed 2023-11-13 | $2.75M derived: sum of 2 quarters · filed 2023-11-13 | $4.12M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $1.44M 10-Q · filed 2023-11-13 | $2.82M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $1.38M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $4.73M 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $1.35M 10-Q · filed 2022-11-21 | $2.64M derived: sum of 2 quarters · filed 2022-11-21 | $3.55M derived: sum of 3 quarters · filed 2022-11-21 | |
| 2021-06-30 | $1.28M 10-Q/A · filed 2022-11-21 | $2.20M derived: sum of 2 quarters · filed 2022-11-21 | ||
| 2021-03-31 | $912.00K 10-Q/A · filed 2022-11-21 | |||
| 2020-12-31 | $2.69M 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $799.00K 10-Q · filed 2021-11-10 | $1.45M derived: sum of 2 quarters · filed 2021-11-10 | $1.88M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $647.00K 10-Q · filed 2021-11-10 | $1.08M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $431.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $572.00K 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $62.00K 10-Q · filed 2020-11-10 | $73.00K derived: sum of 2 quarters · filed 2020-11-10 | $85.00K derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $11.00K 10-Q · filed 2020-11-10 | $23.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $12.00K 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $114.00K 10-K · filed 2020-03-25 | |||
| 2018-09-30 | $10.00K 10-Q · filed 2019-11-12 | $54.00K derived: sum of 2 quarters · filed 2019-11-12 | $100.00K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $44.00K 10-Q · filed 2019-11-12 | $90.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $46.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |